Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics
Cells · 06.03.2023 · 12 (5) · 816
DOI: 10.3390/cells12050816 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 06.03.2023. Verfasst von Albert Leng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Hauptthemen laut MEDLINE: COVID-19, Nervous System Diseases. Die Arbeit wurde bisher 181-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
The development of long-term symptoms of coronavirus disease 2019 (COVID-19) more than four weeks after primary infection, termed “long COVID” or post-acute sequela of COVID-19 (PASC), can implicate persistent neurological complications in up to one third of patients and present as fatigue, “brain fog”, headaches, cognitive impairment, dysautonomia, neuropsychiatric symptoms, anosmia, hypogeusia, and peripheral neuropathy. Pathogenic mechanisms of these symptoms of long COVID remain largely unclear; however, several hypotheses implicate both nervous system and systemic pathogenic mechanisms such as SARS-CoV2 viral persistence and neuroinvasion, abnormal immunological response, autoimmunity, coagulopathies, and endotheliopathy. Outside of the CNS, SARS-CoV-2 can invade the support and stem cells of the olfactory epithelium leading to persistent alterations to olfactory function. SARS-CoV-2 infection may induce abnormalities in innate and adaptive immunity including monocyte expansion, T-cell exhaustion, and prolonged cytokine release, which may cause neuroinflammatory responses and microglia activation, white matter abnormalities, and microvascular changes. Additionally, microvascular clot formation can occlude capillaries and endotheliopathy, due to SARS-CoV-2 protease activity and complement activation, can contribute to hypoxic neuronal injury and blood–brain barrier dysfunction, respectively. Current therapeutics target pathological mechanisms by employing antivirals, decreasing inflammation, and promoting olfactory epithelium regeneration. Thus, from laboratory evidence and clinical trials in the literature, we sought to synthesize the pathophysiological pathways underlying neurological symptoms of long COVID and potential therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
- Department of Neurology, Griffith University School of Medicine, Gold Coast, Brisbane, QLD 4215, Australia.
- Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD 4032, Australia.
- Faculty of Medicine, University of Queensland, Brisbane, QLD 4072, Australia.
- Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4000, Australia.
ORCID-Profile: Albert Leng, Manuj Shah, Lavienraj Premraj, Karin Wildi, Carlos A Pardo, Sung-Min Cho
Förderung
- NHLBI NIH HHS
Zitieren
APA
Leng, A., Shah, M., Ahmad, S. A., Premraj, L., Wildi, K., Li Bassi, G., Pardo, C. A., Choi, A., & Cho, S. M. (2023). Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells, 12(5), 816. https://doi.org/10.3390/cells12050816
Vancouver
Leng A, Shah M, Ahmad SA, Premraj L, Wildi K, Li Bassi G, et al. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12(5):816. doi:10.3390/cells12050816
BibTeX
@article{Leng2023,
author = {Leng, Albert and Shah, Manuj and Ahmad, Syed Ameen and Premraj, Lavienraj and Wildi, Karin and Li Bassi, Gianluigi and Pardo, Carlos A and Choi, Alex and Cho, Sung-Min},
title = {Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics},
journal = {Cells},
year = {2023},
volume = {12},
number = {5},
pages = {816},
doi = {10.3390/cells12050816}
}
EUVIMED